Standard BioTools Inc. Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year
Standard BioTools Inc. (LAB) had Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year of $264.00 thousand as of 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear · last filed 2017-11-07
- 2017-09-30: Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year $264.00K.
| Period end | Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year |
|---|---|
| 2017-09-30 | $264.00K 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |